Advertisement

Topics

PubMed Journals Articles About "Efficacy And Safety Of Empagliflozin (BI 10773) In Patients With Type 2 Diabetes And Renal Impairment" RSS

13:32 EDT 24th March 2019 | BioPortfolio

Efficacy And Safety Of Empagliflozin (BI 10773) In Patients With Type 2 Diabetes And Renal Impairment PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Efficacy And Safety Of Empagliflozin (BI 10773) In Patients With Type 2 Diabetes And Renal Impairment articles that have been published worldwide.

More Information about "Efficacy And Safety Of Empagliflozin (BI 10773) In Patients With Type 2 Diabetes And Renal Impairment" on BioPortfolio

We have published hundreds of Efficacy And Safety Of Empagliflozin (BI 10773) In Patients With Type 2 Diabetes And Renal Impairment news stories on BioPortfolio along with dozens of Efficacy And Safety Of Empagliflozin (BI 10773) In Patients With Type 2 Diabetes And Renal Impairment Clinical Trials and PubMed Articles about Efficacy And Safety Of Empagliflozin (BI 10773) In Patients With Type 2 Diabetes And Renal Impairment for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Efficacy And Safety Of Empagliflozin (BI 10773) In Patients With Type 2 Diabetes And Renal Impairment Companies in our database. You can also find out about relevant Efficacy And Safety Of Empagliflozin (BI 10773) In Patients With Type 2 Diabetes And Renal Impairment Drugs and Medications on this site too.

Showing "Efficacy Safety Empagliflozin 10773 Patients With Type Diabetes" PubMed Articles 1–25 of 52,000+

Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials.

This study was designed to evaluate the efficiency and tolerability of empagliflozin (EMPA) as monotherapy or add-on to existing therapy in patients with type 2 diabetes mellitus (T2DM).


Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME trial.

In the EMPA-REG OUTCOME trial, empagliflozin added to standard of care improved clinically relevant kidney outcomes by 39%, slowed progression of chronic kidney disease, and reduced albuminuria in patients with type 2 diabetes and established cardiovascular disease. This exploratory analysis investigated kidney effects of empagliflozin in Asian patients.

Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume and patient safety.

The safety and efficacy of sodium-glucose cotransporter 2 inhibitors in posttransplantation diabetes mellitus is unknown. We converted stable kidney transplant patients to 10 mg empagliflozin, aiming at replacing their insulin therapy (


Take Control: A Randomized Trial Evaluating the Efficacy and Safety of Self- Versus Physician-Managed Titration of Insulin Glargine 300 U/mL (Gla-300) in Patients with Uncontrolled Type 2 Diabetes.

To compare the efficacy and safety of self- vs physician-managed titration of insulin glargine 300 U/mL (Gla-300), in patients with inadequately controlled type 2 diabetes.

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.

Phase III, randomized, double-blind study evaluating efficacy and safety of ertugliflozin in Asian patients with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin, including evaluation in the China subpopulation.

The efficacy and safety of dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a Bayesian network meta-analysis of 58 randomized controlled trials.

The aim is to evaluate the efficacy and safety of dipeptidyl peptidase-4 inhibitors (DPP4-I: sitagliptin, saxagliptin, linagliptin, vildagliptin and alogliptin) in patients with type 2 diabetes.

Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin up-titration in treatment of patients with type 2 diabetes: the CompoSIT-M Study.

To characterize the glycemic efficacy and safety of initiation of the DPP-4 inhibitor sitagliptin during metformin dose escalation in participants with type 2 diabetes (T2D) not at HbA1c goal on a sub-maximal dose of metformin.

Empagliflozin improves cardiorespiratory fitness in type 2 diabetes: Translational implications.

SGLT2 inhibitors have been shown to prevent heart failure and reduce cardiovascular death in patients with type 2 diabetes (T2DM) and cardiovascular disease (CVD). Whether or not SGLT2 inhibitors improve indices of cardiorespiratory fitness (CRF), an independent predictor of mortality in patients with CVD, remains unknown. We evaluated the effects of empagliflozin on indices of CRF in patients with T2DM. Twenty patients with T2DM received either empagliflozin 10mg or usual care. Baseline and 3 to 6-month po...

Efficacy and Safety of Premixed Human Insulin Combined with Sulfonylureas in Type 2 Diabetic Patients Previously Poorly Controlled with Insulin.

Some type 2 diabetes (T2DM) patients treated with premixed insulin alone or in combination with oral glucose-lowering agents (without sulfonylureas) cannot reach the required glucose targets. Clinical studies have demonstrated that diabetes patients treated with sulfonylureas achieve stable glycemic control, with a low hypoglycemic rate. The aim of our study was to evaluate the efficacy and safety of therapy with the combination of premixed insulin and sulfonylureas.

EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES.

Objective The efficacy and safety of insulin degludec/liraglutide (IDegLira) in older patients has not yet been reported. This analysis aimed to evaluate the efficacy and safety of IDegLira in patients aged ≥65 years. Methods A post hoc analysis compared results of patients aged ≥65 versus

Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial.

Choices of hypoglycemic agents for patients with type 2 diabetes and chronic kidney disease (CKD) are limited. Available data among patients with CKD suggest that pioglitazone was effective and safe, with no increase in serious adverse effects. However, weight gain and fluid retention are major clinical problems for pioglitazone among patients with CKD. We conducted this study to compare the efficacy and side effects of low dose pioglitazone with standard dose pioglitazone among patients with type 2 diabete...

Randomised study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the China Population From the BERSON Clinical Trial.

To evaluate the efficacy and safety of evolocumab with background atorvastatin in Chinese patients with type 2 diabetes mellitus (T2DM) and hyperlipidaemia or mixed dyslipidaemia.

The Favorable Effect of Empagliflozin on Erectile Function in an Experimental Model of Type 2 Diabetes.

Following the results of the EMPA-REG Outcome trial, we hypothesized that empagliflozin, a highly potent and specific sodium/glucose cotransporteur 2 inhibitor, could improve type 2 diabetes mellitus (T2DM)-associated erectile dysfunction (ED), a highly prevalent complication of T2DM, very often coexisting with cardiovascular complications and considered as a prognostic factor of cardiovascular disease in men with diabetes.

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Korean Patients with Type 2 Diabetes Mellitus in Real-World Clinical Practice.

This study aimed to evaluate the efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors in Korean patients who had inadequately controlled type 2 diabetes mellitus (T2DM) in real-world clinical practice.

Safety and efficacy of Melissa officinalis (lemon balm) on ApoA-I, Apo B, lipid ratio and ICAM-1 in type 2 diabetes patients: A randomized, double-blinded clinical trial.

The purpose of this study was to investigate the safety and effects of Melissa officinalis, a good source of bioactive components, on apolipoprotein (Apo)B, Apo A-I, and their ratio, lipids ratios and intercellular adhesion molecule-1(ICAM-1) in patients with type 2 diabetes.

Randomised, phase 1, dose-finding study of MEDI4166, a PCSK9 antibody and GLP-1 analogue fusion molecule, in overweight or obese patients with type 2 diabetes mellitus.

Cardiovascular disease is the leading cause of morbidity and mortality in people with type 2 diabetes. MEDI4166 is a proprotein convertase subtilisin/kexin type 9 (PCSK9) antibody and glucagon-like peptide-1 (GLP-1) analogue fusion molecule designed to treat patients with type 2 diabetes who are at risk for cardiovascular disease. In this completed, first-in-human study, we evaluated the safety and efficacy of single or multiple doses of MEDI4166 in participants with type 2 diabetes.

Effects of empagliflozin on metabolic parameters in polycystic ovary syndrome: a randomised controlled study.

Empagliflozin is a sodium-glucose-cotransporter-2 inhibitor that improves cardiovascular risk and promotes weight loss in patients with type 2 diabetes. Polycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular risk; therefore, empagliflozin may be of benefit for these women. The aim of this study was to compare the effects of empagliflozin vs. metformin on anthropometric and body composition, hormonal and metabolic parameters in women with PCOS.

Impact of Optimum Diabetes Care on the Safety of Fasting in Ramadan in Adult Patients with Type 2 Diabetes Mellitus on Insulin Therapy.

we aimed at evaluating the safety of fasting Ramadan for insulin treated type 2 diabetes patients by assessing the biochemical, biometric parameters, flash glucose monitoring (FGM) data as compared to pre-Ramadan and hospital admissions with diabetes or non-diabetes conditions. The risks of fasting between those treated with basal insulin vs intensive insulin during Ramadan was also assessed.

Type 2 Diabetes Therapies: A STEPS Approach.

A concise way to evaluate pharmacotherapy options for type 2 diabetes mellitus is to use the five patient-oriented STEPS criteria: safety, tolerability, efficacy, price, and simplicity. The first-line treatment option, metformin, is safe and fairly well-tolerated, has excellent long-term efficacy for patient-oriented outcomes, is moderately priced, and has a simple dosing regimen. However, most patients with type 2 diabetes require more than one medication. The STEPS approach can help choose subsequent medi...

Acupuncture and related techniques for type 2 diabetes mellitus: A systematic review protocol.

Type 2 diabetes mellitus (T2DM) is a major global health problem. As a complementary treatment, acupuncture and related techniques are widely used to treat metabolic and endocrine diseases, but their efficacy and safety for T2DM are yet to be established. This systematic review will qualitatively and quantitatively summarize the current randomized controlled trial (RCT) evidence regarding the efficacy and safety of acupuncture and related techniques in patients with T2DM.

Long-Term Treatment with Empagliflozin Attenuates Renal Damage in Obese Zucker Rat.

Empagliflozin, a known inhibitor of sodium-glucose cotransporter type 2 (SGLT2) decreases glucose reabsorption by the renal tubules and promotes glucose excretion into the urine. While the effectiveness of Empagliflozin in the management of hyperglycemia along with associated cardiovascular and all-cause mortality has been demonstrated previously, the therapeutic benefits associated with the long-term use of this drug in obese animals have yet to be investigated.

Efficacy and safety of IdegLira for the intensification of type 2 diabetes treatment.

Diabetes mellitus is a true pandemic; type 2 diabetes in particular, with its progressive nature, constitutes a serious health problem. Despite advances and innovations in treatment, it continues to generate high morbidity and mortality. Many patients do not achieve their metabolic control objectives, due to clinical inertia, fear of hypoglycaemia, weight gain, the complexity of the treatment and the lack of adherence to it. Recently, the clinical results of the combined use of basal insulin and agonist rec...

Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.

In individuals with type 2 diabetes, glycaemic control and cardiovascular risk factor management reduces the likelihood of late-stage diabetic complications. Guidelines recommend treatment goals targeting HbA1c, body weight, blood pressure, and low-density lipoprotein cholesterol. Development of new treatments for type 2 diabetes requires an understanding of their mechanism and efficacy, as well as their relative effects compared to other treatment choices, plus demonstration of cardiovascular safety. Subcu...

News in diabetology 2018.

Diabetes is a rapidly evolving discipline, numerous new molecules and technologies are available. This allows for a better follow up of our patients with type 1 and type 2 diabetes. Moreover, every new molecule devoted to treat type 2 diabetes must undergo a cardiovascular safety study. In recent years, some of these studies proved to be beneficial for some of our patients. Nevertheless, this pharmacological plethora is paradoxically associated with clinical inertia as general practitioners may be in troubl...

The Efficacy and Safety of Pemafibrate in Patients with Type 2 Diabetes and Elevated Triglyceride levels: 52-Week Data From The PROVIDE Study.

This study aimed to evaluate the efficacy and safety of pemafibrate in patients with type 2 diabetes and hypertriglyceridemia over a 52-week period. Patients were randomly assigned to receive treatment with placebo or pemafibrate at a dose of 0.2 or 0.4 mg/day for 24 weeks (treatment period 1). The main results from treatment period 1 have been reported previously. The assigned treatment was continued up to week 52, except that the placebo was changed to pemafibrate 0.2 mg/day after week 24 (treatment perio...


Advertisement
Quick Search
Advertisement
Advertisement